Available Technologies

Executive Summary

There are several existing cancer treatments that are effective at inducing cell death by decreasing proteasome activity: Velcade® (bortezomib) and Kyprolis® (carfilzomib). Due to undesirable side effects and pharmacodynamics properties, these agents have been limited to treating blood cancers.  MSU researchers have developed a new class of therapeutic compounds with a unique mode of action and more promising pharmacodynamics. 

Description of Technology

This technology uses a new class of quinoline-based proteasome inhibitors. These compounds differ from previous proteasome inhibitors by exhibiting uncompetitive reversible inhibition rather than competitive inhibition. This technology is effective against bortezomib-resistant Multiple Myeloma cells and has potential as a novel asthma treatment.

Key Benefits

• Effective against drug-resistant myeloma cells
• Has potential to target other cancers and diseases
• Novel mechanism of inhibition
• Simple chemical synthesis

Applications

• Treating Multiple Myeloma
• Inhibit proteasome function to kill cancer cell
• Effective against bortezomib-resistant strains
• Treating asthma
• Same inhibition pathway

Patent Status: 

Under review

Licensing Rights Available

Full licensing rights available

Inventors: Aaron Odom, Jetze Tepe, Teri Lansdall

Tech ID: TEC2016-0123

Alternative contact due to temporary leave:

Nina (Isi) Davis, Technology Marketing Manager, email: davisnin@msu.edu, phone (direct): (517)884-1829.